智慧胰島素筆市場規模 - 按產品類型、連接類型、應用和分銷管道 - 區域前景、競爭策略和細分市場預測（截至 2033 年）

預計2033年，全球智慧胰島素筆市場規模將成長至20,5411萬美元，年複合成長率為10.69%。

COVID-19 期間前往醫院和糖尿病中心的患者減少，導致智慧胰島素筆處方減少。此外，配送鏈問題導致零售店購買困難，銷售量減少。與大流行相關的經濟放緩使消費者更加重視成本，並減少了昂貴的系留胰島素筆的市場。

本報告調查了全球智慧胰島素筆市場，並提供了市場概況、市場影響因素和市場機會分析、市場規模趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業。。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第4章市場動態

• 促進因素、抑制因素、機會與挑戰分析
• COVID-19 對市場的影響

第5章 市場變數與展望

• SWOT分析
• PESTEL分析
• 波特五力分析
• 熱圖分析

第6章 競爭狀況

• 製造地、銷售區域、產品類型分佈
• 併購、聯盟、產品發布、合作

第7章全球智慧型胰島素筆市場：依產品

• 全球市佔率及預測
• 智慧胰島素筆
• 傳統筆的適配器

第8章全球智慧型胰島素筆市場：按連接類型

• 全球市佔率及預測
• Bluetooth
• USB

第9章全球智慧型胰島素筆市場：依應用分類

• 全球市佔率及預測
• 1型糖尿病
• 2型糖尿病

第10章全球智慧胰島素筆市場：依通路分類

• 全球市佔率及預測
• 醫院藥房
• 網上銷售
• 零售藥房
• 糖尿病診所/中心

第11章全球智慧胰島素筆市場預測

• 市場規模/市場佔有率

第12章全球智慧胰島素筆市場：依產品類型

• 市場規模/市場佔有率趨勢/預測

第13章全球智慧胰島素筆市場：按連結類型

• 市場規模/市場佔有率趨勢/預測

第14章全球智慧胰島素筆市場：依應用分類

• 市場規模/市場佔有率趨勢/預測

第15章全球智慧胰島素筆市場：依通路分類

• 市場規模/市場佔有率趨勢/預測

第16章全球智慧型胰島素筆市場：按地區

• 市場規模/市場佔有率趨勢/預測
• 亞太地區
• 歐洲
• 中東/非洲
• 北美洲
• 拉丁美洲

第17章 公司簡介

• Bigfoot Biomedical
• Diamesco Co. Ltd.
• Eli Lilly and Company
• Emperra GmbH
• Jiangsu Deflu Medical Device Co. Ltd.
• Medtronic plc
• Novo Nordisk A/S
• Pendiq
• Sanofi (Sanofi-Aventis US LLC)
• Ypsomed Holding AG
• 其他

第18章簡稱

第19章 參考鏈接

第20章結論

第21章 研究範圍

Smart Insulin Pens Market Introduction and Overview

According to SPER market research, Smart Insulin Pens Market Size- By Product, By Connectivity Type, By Application, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Smart Insulin Pens Market is predicted to reach USD 2054.11 Million by 2033 with a CAGR of 10.69%.

Smart insulin pens provide an accessible option for exogenous insulin administration and diabetes treatment. It is a reusable injector pen that works with a simple app on a smartphone which allow for wireless data transfer to the app. This intelligent system keeps track of dosages and generates reports, useful notifications, and half-unit doses that are exact. In addition, it alerts patients whenever insulin is about to expire or reaches its temperature spectrum, allowing them to change the cartridge and provide diabetic information to the medical staff as needed.

There was a decrease in the number of prescriptions for smart insulin pens as a result of fewer patients visiting hospitals and diabetic centers during the COVID 19 pandemic. Additionally, the accessibility of these pens at retail stores was disrupted by problems in the delivery chain, which led to a decrease in sales. The pandemic-related economic slowdown made consumers more cost-conscious, which decreased the market for expensive connected insulin pens.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Product, By Connectivity Type, By Application, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Bigfoot Biomedical, Diamesco Co. Ltd., Eli Lilly and Company, Emperra GmbH, Jiangsu Deflu Medical Device Co. Ltd., Medtronic plc, Novo Nordisk A/S, Pendiq, Sanofi (Sanofi-Aventis US LLC), Ypsomed Holding AG, and others.

Smart Insulin Pens Market Segmentation

By Product: Based on the Product, Global Smart Insulin Pens Market is segmented as; Smart Insulin Pens, Adaptors for Conventional Pens

By Application: Based on the Application, Global Smart Insulin Pens Market is segmented as; Type 1 Diabetes, Type 2 Diabetes

By Distribution Channel: Based on the Distribution Channel, Global Smart Insulin Pens Market is segmented as; Hospital Pharmacies, Online Sales, Retail Pharmacies, Diabetes Clinics/Centers

Table of Contents

1.Introduction

• 1.1.Scope of the report
• 1.2.Market segment analysis

2.Research Methodology

• 2.1.Research data source
  • 2.1.1.Secondary Data
  • 2.1.2.Primary Data
  • 2.1.3.SPER's internal database
  • 2.1.4.Premium insight from KOL's
• 2.2.Market size estimation
  • 2.2.1.Top-down and Bottom-up approach
• 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

• 4.1.Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1.Drivers
  • 4.1.2.Restraints
  • 4.1.3.Opportunities
  • 4.1.4.Challenges
• 4.2.COVID-19 Impacts of the Global Smart Insulin Pens Market

5.Market variable and outlook

• 5.1.SWOT Analysis
  • 5.1.1.Strengths
  • 5.1.2.Weaknesses
  • 5.1.3.Opportunities
  • 5.1.4.Threats
• 5.2.PESTEL Analysis
  • 5.2.1.Political Landscape
  • 5.2.2.Economic Landscape
  • 5.2.3.Social Landscape
  • 5.2.4.Technological Landscape
  • 5.2.5.Environmental Landscape
  • 5.2.6.Legal Landscape
• 5.3.PORTER's Five Forces
  • 5.3.1.Bargaining power of suppliers
  • 5.3.2.Bargaining power of buyers
  • 5.3.3.Threat of Substitute
  • 5.3.4.Threat of new entrant
  • 5.3.5.Competitive rivalry
• 5.4.Heat Map Analysis

6.Competitive Landscape

• 6.1.Global Smart Insulin Pens Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Smart Insulin Pens Market

7.Global Smart Insulin Pens Market, By Product (USD Million)

• 7.1.Global Smart Insulin Pens Market Value Share and Forecast, By Product, 2024-2033
• 7.2.Smart Insulin Pens
• 7.3.Adaptors for Conventional Pens

8.Global Smart Insulin Pens Market, By Connectivity Type (USD Million)

• 8.1.Global Smart Insulin Pens Market Value Share and Forecast, By Connectivity Type, 2024-2033
• 8.2.Bluetooth
• 8.3.USB

9.Global Smart Insulin Pens Market, By Application (USD Million)

• 9.1.Global Smart Insulin Pens Market Value Share and Forecast, By Application, 2024-2033
• 9.2.Type 1 Diabetes
• 9.3.Type 2 Diabetes

10.Global Smart Insulin Pens Market, By Distribution Channel (USD Million)

• 10.1.Global Smart Insulin Pens Market Value Share and Forecast, By Distribution Channel, 2024-2033
• 10.2.Hospital Pharmacies
• 10.3.Online Sales
• 10.4.Retail Pharmacies
• 10.5.Diabetes Clinics/Centers

11.Global Smart Insulin Pens Market Forecast, 2020-2033 (USD Million)

• 11.1.Global Smart Insulin Pens Market Size and Market Share

12.Global Smart Insulin Pens Market, By Product Type 2020-2033 (USD Million)

• 12.1.Global Smart Insulin Pens Market Size and Market Share By Product (2020-2026)
• 12.2.Global Smart Insulin Pens Market Size and Market Share By Product (2027-2033)

13.Global Smart Insulin Pens Market, By Connectivity Type, 2020-2033 (USD Million)

• 13.1.Global Smart Insulin Pens Market Size and Market Share By Connectivity Type (2020-2026)
• 13.2.Global Smart Insulin Pens Market Size and Market Share By Connectivity Type (2027-2033)

14.Global Smart Insulin Pens Market, By Application, 2020-2033 (USD Million)

• 14.1.Global Smart Insulin Pens Market Size and Market Share By Application (2020-2026)
• 14.2.Global Smart Insulin Pens Market Size and Market Share By Application (2027-2033)

15.Global Smart Insulin Pens Market, By Distribution Channel, 2020-2033 (USD Million)

• 15.1.Global Smart Insulin Pens Market Size and Market Share By Distribution Channel (2020-2026)
• 15.2.Global Smart Insulin Pens Market Size and Market Share By Distribution Channel (2027-2033)

16.Global Smart Insulin Pens Market, By Region, 2020-2033 (USD Million)

• 16.1.Global Smart Insulin Pens Market Size and Market Share By Region (2020-2026)
• 16.2.Global Smart Insulin Pens Market Size and Market Share By Region (2027-2033)
• 16.3.Asia-Pacific
  • 16.3.1.Australia
  • 16.3.2.China
  • 16.3.3.India
  • 16.3.4.Japan
  • 16.3.5.South Korea
  • 16.3.6.Rest of Asia-Pacific
• 16.4.Europe
  • 16.4.1.France
  • 16.4.2.Germany
  • 16.4.3.Italy
  • 16.4.4.Spain
  • 16.4.5.United Kingdom
  • 16.4.6.Rest of Europe
• 16.5.Middle East and Africa
  • 16.5.1.Kingdom of Saudi Arabia
  • 16.5.2.United Arab Emirates
  • 16.5.3.Rest of Middle East & Africa
• 16.6.North America
  • 16.6.1.Canada
  • 16.6.2.Mexico
  • 16.6.3.United States
• 16.7.Latin America
  • 16.7.1.Argentina
  • 16.7.2.Brazil
  • 16.7.3.Rest of Latin America

17.Company Profile

• 17.1.Bigfoot Biomedical
  • 17.1.1.Company details
  • 17.1.2.Financial outlook
  • 17.1.3.Product summary
  • 17.1.4.Recent developments
• 17.2.Diamesco Co. Ltd.
  • 17.2.1.Company details
  • 17.2.2.Financial outlook
  • 17.2.3.Product summary
  • 17.2.4.Recent developments
• 17.3.Eli Lilly and Company
  • 17.3.1.Company details
  • 17.3.2.Financial outlook
  • 17.3.3.Product summary
  • 17.3.4.Recent developments
• 17.4.Emperra GmbH
  • 17.4.1.Company details
  • 17.4.2.Financial outlook
  • 17.4.3.Product summary
  • 17.4.4.Recent developments
• 17.5.Jiangsu Deflu Medical Device Co. Ltd.
  • 17.5.1.Company details
  • 17.5.2.Financial outlook
  • 17.5.3.Product summary
  • 17.5.4.Recent developments
• 17.6.Medtronic plc
  • 17.6.1.Company details
  • 17.6.2.Financial outlook
  • 17.6.3.Product summary
  • 17.6.4.Recent developments
• 17.7.Novo Nordisk A/S
  • 17.7.1.Company details
  • 17.7.2.Financial outlook
  • 17.7.3.Product summary
  • 17.7.4.Recent developments
• 17.8.Pendiq
  • 17.8.1.Company details
  • 17.8.2.Financial outlook
  • 17.8.3.Product summary
  • 17.8.4.Recent developments
• 17.9.Sanofi (Sanofi-Aventis US LLC)
  • 17.9.1.Company details
  • 17.9.2.Financial outlook
  • 17.9.3.Product summary
  • 17.9.4.Recent developments
• 17.10.Ypsomed Holding AG
  • 17.10.1.Company details
  • 17.10.2.Financial outlook
  • 17.10.3.Product summary
  • 17.10.4.Recent developments
• 17.11.Others

18.List of Abbreviations

19.Reference Links

20.Conclusion

21.Research Scope